STERIS plc

NYSE:STE 주식 리포트

시가총액: US$21.5b

STERIS 향후 성장

Future 기준 점검 1/6

STERIS (는) 각각 연간 9.5% 및 6.2% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 9.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.8% 로 예상됩니다.

핵심 정보

9.5%

이익 성장률

9.57%

EPS 성장률

Medical Equipment 이익 성장16.1%
매출 성장률6.2%
향후 자기자본이익률12.80%
애널리스트 커버리지

Good

마지막 업데이트13 May 2026

최근 향후 성장 업데이트

Recent updates

내러티브 업데이트 • May 11

STE: Lower Discount Rate And Stable Assumptions Will Support Future Upside

Analysts have maintained their $279.29 price target for STERIS, supported by a slightly lower discount rate and minor adjustments to long-term revenue growth, profit margin, and future P/E assumptions. Valuation Changes Fair Value: Maintained at $279.29 per share, with no change in the updated analysis.
내러티브 업데이트 • Apr 26

STE: Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have reiterated a $279.29 price target for STERIS, citing largely unchanged assumptions on growth, margins, discount rate and future P/E as the basis for maintaining their current valuation framework. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares under an existing buyback program (Key Developments).
내러티브 업데이트 • Apr 11

STE: Completed Buyback And Stable Assumptions Will Support Future Upside

Analysts kept their fair value estimate for STERIS steady at about $279 per share, while slightly updating assumptions around discount rate, revenue growth, profit margin, and future P/E. This reflects fine tuning of their models rather than a shift in the core outlook.
내러티브 업데이트 • Mar 28

STE: Completed Buyback And Refined Assumptions Will Support Future Upside

Analysts have reduced their price target on STERIS by about $2 to reflect slightly updated assumptions for fair value, discount rate, revenue growth, profit margin, and forward P/E, while maintaining the overall thesis. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, accounting for 0.2% of its shares.
분석 기사 • Mar 24

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) received a lot of attention from a substantial price movement on the NYSE over the last few...
내러티브 업데이트 • Mar 11

STE: Completed Share Repurchases And Stable Assumptions Will Support Future Upside

Analysts have kept their STERIS price target steady at $281.25, with only minor tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock's valuation. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of shares.
내러티브 업데이트 • Feb 25

STE: Completed Share Repurchases And Steady Assumptions Will Support Future Upside

Analysts have slightly trimmed their fair value estimate for STERIS to about $281 from roughly $282, reflecting modest tweaks to assumptions on the discount rate, long term revenue growth, profit margin, and future P/E expectations. What's in the News From October 1, 2025 to December 31, 2025, STERIS repurchased 200,000 shares for US$51.96 million, representing 0.2% of its shares.
내러티브 업데이트 • Feb 10

STE: Modest Assumption Tweaks Will Support A More Upbeat Fair View

Analysts have slightly adjusted their price target for STERIS to US$281.63, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Together, these factors suggest a modest recalibration of expectations rather than a major shift in outlook.
Seeking Alpha • Feb 06

STERIS: A Bump In The Road For A Reliable Name

Summary STERIS offers a resilient, high-quality business model with some premium valuation, benefiting from hard-to-replicate sterilization networks and stable healthcare procedure volumes. Recent quarterly results included on-target 8% organic revenue growth but margin pressure from tariffs, with management raising tariff impact guidance by $10 million. STE stands to gain from stricter ethylene oxide (EtO) regulations, as compliance costs favor large, established players and will drive more outsourcing to its facilities. While not deeply undervalued, STE provides credible GARP appeal, stable cash flows, and less execution risk versus more volatile medtech peers. Read the full article on Seeking Alpha
내러티브 업데이트 • Jan 27

STE: Share Repurchases And Stable Outlook Will Support A Fair View

Analysts have kept their fair value estimate for STERIS steady at about $281.63 per share, while making only very small tweaks to assumptions such as the discount rate and future P/E, reflecting largely unchanged views on the company’s long term earnings power. What's in the News From July 1, 2025 to September 30, 2025, STERIS repurchased 400,000 shares, representing 0.41% of its shares, for $98.64 million under its existing buyback program (Key Developments).
내러티브 업데이트 • Jan 10

STE: Share Repurchases And Steady Guidance Will Support A Fair Outlook

Analysts have kept their fair value estimate for STERIS essentially unchanged at about US$281.63, citing only very small tweaks to assumptions such as the discount rate, revenue growth, profit margin and future P/E that do not materially affect their overall price target view. What's in the News STERIS repurchased 400,000 shares from July 1, 2025 to September 30, 2025, representing 0.41% of shares for US$98.64 million, as part of its ongoing buyback program.
분석 기사 • Jan 09

Here's Why STERIS (NYSE:STE) Has Caught The Eye Of Investors

Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
분석 기사 • Dec 26

Earnings Tell The Story For STERIS plc (NYSE:STE)

With a price-to-earnings (or "P/E") ratio of 36.4x STERIS plc ( NYSE:STE ) may be sending very bearish signals at the...
내러티브 업데이트 • Dec 23

STE: Share Repurchases And Steady Guidance Will Support A Fair Future Outlook

Analysts have modestly raised their price target on STERIS to $281.63, reflecting slightly higher long term growth and profitability expectations, despite largely unchanged model assumptions. What's in the News STERIS completed a share repurchase tranche between July 1 and September 30, 2025, buying back 400,000 shares, or 0.41% of shares outstanding, for $98.64 million (Key Developments).
내러티브 업데이트 • Dec 09

STE: Modest Buybacks And Steady Guidance Will Support A Balanced Outlook

Analysts have modestly raised their price target on STERIS to approximately $282 per share from about $281.60, reflecting slightly lower perceived risk and a steady outlook for revenue growth, profit margins, and long term valuation multiples. What's in the News Completed a share repurchase program totaling 1,307,158 shares, or about 1.32% of shares outstanding, for $298.64 million under the buyback announced on May 3, 2023 (company filing).
내러티브 업데이트 • Nov 25

STE: Stable Outlook And Share Buybacks Will Shape Near-Term Performance

Analysts have raised their price target for STERIS from $278.38 to $281.63. This change reflects modest expectations for improved revenue growth, even though there have been minor adjustments to other key financial metrics.
내러티브 업데이트 • Nov 07

STE: Marginal Profit Margin Gains And Steady Outlook Will Influence Value

Analysts have raised their price target for STERIS from $272.38 to $278.38. They cite marginal improvements in projected profit margins, even though revenue growth expectations have been slightly reduced.
분석 기사 • Oct 27

Is STERIS (NYSE:STE) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
내러티브 업데이트 • Sep 05

Healthcare Demand And Facility Expansion Will Create Value

With STERIS’s discount rate and future P/E both virtually unchanged, analyst valuation perspectives remain steady, resulting in an unchanged consensus price target of $272.38. What's in the News STERIS completed $200 million in share repurchases, totaling 907,158 shares (0.92%) under its current buyback program; no additional shares were repurchased in the latest quarter.
분석 기사 • Aug 28

Calculating The Fair Value Of STERIS plc (NYSE:STE)

Key Insights STERIS' estimated fair value is US$227 based on 2 Stage Free Cash Flow to Equity With US$249 share price...
분석 기사 • Aug 07

STERIS (NYSE:STE) Is Paying Out A Larger Dividend Than Last Year

The board of STERIS plc ( NYSE:STE ) has announced that it will be increasing its dividend by 11% on the 26th of...
분석 기사 • Jul 06

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

STERIS plc ( NYSE:STE ) saw a double-digit share price rise of over 10% in the past couple of months on the NYSE. The...
분석 기사 • May 23

Is Now The Time To Put STERIS (NYSE:STE) On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Seeking Alpha • Mar 22

Steris: AST Recovery Is Ongoing; Upgrading To 'Strong Buy'

Summary Upgraded Steris to 'strong buy' with a fair value of $254 per share due to strong recovery in its Applied Sterilization Technologies (AST) business. AST segment showed 9.5% organic growth, with management confident in further recovery despite challenges from rising labor costs and raw material inflation. For FY25, Steris guides for 6% revenue growth and 3.1% adjusted EPS growth, with significant contributions expected from Healthcare Products and AST segments. Key risks include weak capital equipment sales due to economic conditions, but overall, Steris's differentiated AST portfolio supports a positive long-term outlook. Read the full article on Seeking Alpha
Seeking Alpha • Nov 18

Steris Q2: Anticipating HSD Growth In AST, Upgrade To 'Buy'

Summary I am upgrading STERIS to a 'Buy' with a fair value of $240 per share due to the recent stock price pullback and solid growth prospects. STERIS reported 7.2% organic revenue growth and 5.4% adjusted EPS growth, with strong performance in the Applied Sterilization Technologies segment. Despite high interest rates, I anticipate a gradual recovery in the biotech industry, driving future double-digit revenue growth in STERIS' AST business. Key risks include potential legal liabilities from EtO emissions and weak near-term growth in healthcare capital equipment revenue. Read the full article on Seeking Alpha
Seeking Alpha • Sep 16

Steris: Dental Divestiture, Surgical Instrumentation Acquisition, But Overvalued

Summary I reiterate a 'Hold' rating for Steris stock with a fair value of $220 per share, citing strong healthcare growth and overvaluation concerns. The divestiture of the dental business and acquisition of Surgical Instrumentation assets will allow Steris to focus on core healthcare and AST businesses. Steris reported 5.4% organic revenue growth and 7% adjusted EPS growth, driven by a 7.2% increase in AST business and strong healthcare performance. Despite strategic moves, cautious outlook on healthcare capital equipment spending due to high-interest rates supports maintaining a 'Hold' rating. Read the full article on Seeking Alpha
User avatar
새로운 내러티브 • Aug 20

Robust Revenue Growth And Expanding Margins In The Medical Equipment Sector

Strong start to the fiscal year and gross margin improvements suggest underappreciated growth momentum and potential for expanding net margins.
Seeking Alpha • Aug 13

Steris: Q2 Numbers Solidify Buy Thesis

Summary STE's Q1 FY'25 numbers were in line with expectations, with upsides in the healthcare and AST divisions. The company shows consistent free cash flow production and stable earnings on its capital base. I've revised our estimate on the intrinsic worth of the business to $270 per share, reiterating a buy. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NYSE:STE - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
3/31/20297,1861,045N/AN/A2
3/31/20286,7729849781,4277
3/31/20276,3618878441,2758
3/31/20265,9367829721,341N/A
12/31/20255,8287099171,267N/A
9/30/20255,7026899611,301N/A
6/30/20255,5716489091,264N/A
3/31/20255,4606107781,148N/A
12/31/20245,3986177511,142N/A
9/30/20245,3265916801,101N/A
6/30/20245,235561594996N/A
3/31/20245,139551613973N/A
12/31/20234,6831,036594934N/A
9/30/20234,6011,012535849N/A
6/30/20234,563576494806N/A
3/31/20234,536557395757N/A
12/31/20224,784-28349713N/A
9/30/20224,777-8399752N/A
6/30/20224,773377472819N/A
3/31/20224,223285397685N/A
12/31/20214,248279412701N/A
9/30/20213,848250400662N/A
6/30/20213,407286424653N/A
3/31/20213,108397450690N/A
12/31/20203,057433476701N/A
9/30/20203,022424400627N/A
6/30/20203,003413384615N/A
3/31/20203,031408376591N/A
12/31/20192,976393N/A570N/A
9/30/20192,898336N/A573N/A
6/30/20192,840319N/A548N/A
3/31/20192,782304N/A540N/A
12/31/20182,730269N/A490N/A
9/30/20182,696316N/A467N/A
6/30/20182,651303N/A478N/A
3/31/20182,620291N/A458N/A
12/31/20172,585243N/A463N/A
9/30/20172,570144N/A453N/A
6/30/20172,582120N/A424N/A
3/31/20172,613110N/A424N/A
12/31/20162,616142N/A439N/A
9/30/20162,588167N/A364N/A
6/30/20162,431135N/A294N/A
3/31/20162,233111N/A255N/A
12/31/20152,04294N/A185N/A
9/30/20151,897113N/A221N/A
6/30/20151,870135N/A241N/A

애널리스트 향후 성장 전망

수입 대 저축률: STE 의 연간 예상 수익 증가율(9.5%)이 saving rate(3.5%)보다 높습니다.

수익 vs 시장: STE 의 연간 수익(9.5%)이 US 시장(16.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 수익: STE 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: STE 의 수익(연간 6.2%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: STE 의 수익(연간 6.2%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: STE의 자본 수익률은 3년 후 12.8%로 낮을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/22 13:41
종가2026/05/22 00:00
수익2026/03/31
연간 수익2026/03/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

STERIS plc는 18명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Michael PolarkBaird
Erin Wilson WrightBofA Global Research
David TurkalyCitizens JMP Securities, LLC